181 related articles for article (PubMed ID: 33747205)
1. Status of CHEK2 and p53 in patients with early-onset and conventional gastric cancer.
Machlowska J; Kapusta P; Szlendak M; Bogdali A; Morsink F; Wołkow P; Maciejewski R; Offerhaus GJA; Sitarz R
Oncol Lett; 2021 May; 21(5):348. PubMed ID: 33747205
[TBL] [Abstract][Full Text] [Related]
2. Programmed death-1 and PD-1 ligand-1 expression in early onset gastric carcinoma and correlation with clinicopathological characteristics.
Wei P; Jin M; Zhou X; Hu X; Wang Y
Int J Clin Exp Pathol; 2018; 11(4):1989-1998. PubMed ID: 31938305
[No Abstract] [Full Text] [Related]
3. Expression profile of E-cadherin, estrogen receptors, and P53 in early-onset gastric cancers.
Zhou F; Xu Y; Shi J; Lan X; Zou X; Wang L; Huang Q
Cancer Med; 2016 Dec; 5(12):3403-3411. PubMed ID: 27781410
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the Expression of CHK2 and p53 in Tumor Tissue and the Course of Papillary Thyroid Cancer in Patients with
Gąsior-Perczak D; Kowalik A; Kopczyński J; Macek P; Niemyska K; Walczyk A; Gruszczyński K; Siołek M; Dróżdż T; Kosowski M; Pałyga I; Przybycień P; Wabik O; Góźdź S; Kowalska A
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398207
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Molecular and Genetic Characteristics of Early Onset Gastric Cancer: Analysis of a Large Multicenter Study.
Pocurull A; Herrera-Pariente C; Carballal S; Llach J; Sánchez A; Carot L; Botargues JM; Cuatrecasas M; Ocaña T; Balaguer F; Bujanda L; Moreira L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201547
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological characteristics of early-onset gastric cancer and its evolutionary trends: a retrospective study.
Qu X; Zhao X; Liu Y; Wang N; Zhang L; Zhu X; Dong Q; Liu J; Shi Y
Am J Cancer Res; 2022; 12(6):2757-2769. PubMed ID: 35812046
[TBL] [Abstract][Full Text] [Related]
7. Mutations in CHEK2 associated with prostate cancer risk.
Dong X; Wang L; Taniguchi K; Wang X; Cunningham JM; McDonnell SK; Qian C; Marks AF; Slager SL; Peterson BJ; Smith DI; Cheville JC; Blute ML; Jacobsen SJ; Schaid DJ; Tindall DJ; Thibodeau SN; Liu W
Am J Hum Genet; 2003 Feb; 72(2):270-80. PubMed ID: 12533788
[TBL] [Abstract][Full Text] [Related]
8. High-Throughput Sequencing of Gastric Cancer Patients: Unravelling Genetic Predispositions Towards an Early-Onset Subtype.
Machlowska J; Kapusta P; Baj J; Morsink FHM; Wołkow P; Maciejewski R; Offerhaus GJA; Sitarz R
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708070
[TBL] [Abstract][Full Text] [Related]
9. Absence of EIF1AX, PPM1D, and CHEK2 mutations reported in Thyroid Cancer Genome Atlas (TCGA) in a large series of thyroid cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem MM; AlGhamdi B; Moria Y; Al-Hindi H
Endocrine; 2019 Jan; 63(1):94-100. PubMed ID: 30269267
[TBL] [Abstract][Full Text] [Related]
10. CHEK2 gene alterations independently increase the risk of death from breast cancer in Bulgarian patients.
Angelova SG; Krasteva ME; Gospodinova ZI; Georgieva EI
Neoplasma; 2012; 59(6):622-30. PubMed ID: 22862163
[TBL] [Abstract][Full Text] [Related]
11. Comparative investigation of early-onset gastric cancer.
Ma Z; Liu X; Paul ME; Chen M; Zheng P; Chen H
Oncol Lett; 2021 May; 21(5):374. PubMed ID: 33777198
[TBL] [Abstract][Full Text] [Related]
12. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
[TBL] [Abstract][Full Text] [Related]
13. Prediction of TP53 mutations by p53 immunohistochemistry and their prognostic significance in gastric cancer.
Hwang HJ; Nam SK; Park H; Park Y; Koh J; Na HY; Kwak Y; Kim WH; Lee HS
J Pathol Transl Med; 2020 Sep; 54(5):378-386. PubMed ID: 32601264
[TBL] [Abstract][Full Text] [Related]
14. Clinical Significance of DNA Damage Response Factors and Chromosomal Instability in Primary Lung Adenocarcinoma.
Okamoto T; Kohno M; Ito K; Takada K; Katsura M; Morodomi Y; Toyokawa G; Shoji F; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1729-1735. PubMed ID: 28373435
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: with respect to histological subtypes and stages.
Wu MS; Shun CT; Sheu JC; Wang HP; Wang JT; Lee WJ; Chen CJ; Wang TH; Lin JT
J Gastroenterol Hepatol; 1998 Mar; 13(3):305-10. PubMed ID: 9570245
[TBL] [Abstract][Full Text] [Related]
16. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.
Zheng L; Wang F; Qian C; Neumann RM; Cheville JC; Tindall DJ; Liu W
Hum Mutat; 2006 Oct; 27(10):1062-3. PubMed ID: 16941491
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
[TBL] [Abstract][Full Text] [Related]
18. The Endoscopic and Clinicopathological Characteristics of Early-onset Gastric Cancer in Vietnamese Patients.
Quach DT; Ha DV; Hiyama T
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1883-1886. PubMed ID: 30049355
[TBL] [Abstract][Full Text] [Related]
19. Potentially pathogenic germline CHEK2 c.319+2T>A among multiple early-onset cancer families.
Dominguez-Valentin M; Nakken S; Tubeuf H; Vodak D; Ekstrøm PO; Nissen AM; Morak M; Holinski-Feder E; Martins A; Møller P; Hovig E
Fam Cancer; 2018 Jan; 17(1):141-153. PubMed ID: 28608266
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Alternative Splicing Events Associated With Tumorigenesis, Protein Modification, and Immune Microenvironment in Early-Onset Gastric Cancer.
Zhang J; Goel A; Zhu L
Front Oncol; 2021; 11():640272. PubMed ID: 34168979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
